liquid biopsy News
-
SAGA Diagnostics appoints Peter Collins as Chief Executive Officer
SAGA Diagnostics AB, (“SAGA”), a leading cancer liquid biopsy and genomic testing company, is pleased to announce the appointment of Peter Collins as Chief Executive Officer. Mr. Collins is a highly experienced entrepreneur with over 30 years of experience in the pharma and diagnostics sector. He joins SAGA after successful executive roles at major players in the liquid biopsy field ...
-
Bio-Techne Announces Paper Publication in Annals of Oncology
This review paper provides unique insight into liquid biopsies and the field of exosomes in the context of other liquid biopsies such as cfDNA and CTC analysis. The exosome field has gone through a rapid growth phase in parallel with the increasing attention over the potential of liquid biopsies. Bio-Techne Corporation (NASDAQ:TECH) today announced that Exosome Diagnostics, a Bio-Techne ...
-
Rarecells, Inc. announces Appointment of Dr. Neil Gunn as New Director to the Board
Rarecells, Inc. today announced the appointment of Dr. Neil Gunn, a recognized leader and expert in the diagnostic space, as an independent Board Director. “We are delighted to welcome Neil as Board Director. With his broad understanding of diagnostics and the Liquid Biopsy space he is well-positioned to provide valuable perspectives and insight across a broad spectrum of topics, from ...
-
Tethis’ Reconfirmed Scientific Advisory Board appoints Prof. Nicola Aceto, Ph.D as Chairman
Tethis S.p.A announced today that in the first meeting of the reconfirmed Scientific Advisory Board held today, Nicola Aceto PhD, Professor of Molecular Oncology at the Swiss Federal Institute of Technology (ETH) Zurich, has been appointed as its new chairman. Prof. Aceto is a world-renowned leader in circulating tumor cell research, and his work on CTC clusters has been published in the highest ...
By Tethis S.p.A
-
Stilla and Promega Announce Co-Marketing Agreement to Offer Complete Digital PCR Workflow Solution
Stilla Technologies, the multiplex digital PCR company, and Promega Corporation today announced a co-marketing agreement that combines sample preparation with the latest Maxwell® systems and digital PCR on the six-color naica® system. With this partnership, the companies will offer an optimized workflow for a wide range of applications including liquid biopsy, sentinel pathogen testing, ...
-
The US Patent Office Grants BIOMARK Additional Patent for its LIQUID BIOPSY Technology
Vancouver, British Columbia – (September 20, 2022) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today that the US Patent Office (USPTO) has granted BioMark patent number US 11,447,168 that covers a novel approach to diagnosing ...
-
Bastiaan van der Baan and Miro Venturi join Tethis as Independent Members of the Board of Directors
Tethis S.p.A, a developer of a novel platform for liquid biopsy testing, announced the appointment of Mr. Bastiaan van der Baan and Mr. Miro Venturi as Independent Members of the Board of Directors. Bastiaan van der Baan, MSc, is currently Chief Clinical and Business Officer at oncology diagnostics test provider Agendia, where he has helped building up the company’s global clinical and ...
By Tethis S.p.A
-
SAGA Diagnostics enters into Development Agreement with AstraZeneca
SAGA Diagnostics AB, a cancer liquid biopsy and genomic testing company focused on precision oncology and non-invasive ultrasensitive monitoring of cancer patients, has entered into an assay development agreement with the global, science-led biopharmaceutical company AstraZeneca (LSE/STO/Nasdaq: AZN). SAGA Diagnostics will in the course of this agreement develop unique SAGAsafe® dPCR ...
-
IMBDx to Attend Bio Health Worldwide Online 2020
IMB Dx is attending the ‘Bio Health Worldwide Online 2020’ exhibit sponsored by KOTRA and the South Korean Ministry of Trade, Industry and Energy which will be held for 12 days beginning October 19th, 2020. Over 500 companies in the fields of biotechnology, pharmaceutical, medical device, healthcare, dietary supplements, and protective supplies, as well as over 1,000 potential buyers ...
By IMB Dx, Inc.
-
Now recruiting: Bioinformatics Scientist
Do you want to help usher in advanced cancer diagnostics and monitoring to improve patient quality of life and survival? SAGA Diagnostics AB is seeking a talented and highly motivated Bioinformatics Scientist with strong interest in advancing our mission to revolutionize cancer diagnostics through proprietary ultrasensitive technologies that measure circulating tumor DNA (ctDNA) in ...
-
Study published in BJC shows strong performance of Tethis’ liquid biopsy test in early stage breast cancer
Study Published in British Journal of Cancer Shows High Sensitivity and Specificity of Tethis’ Liquid Biopsy Platform in Early Stage Breast Cancer and the Identification of Circulating Tumor Cells Clusters for the First Time in Non-Metastatic Patients Tethis S.p.A announced the publication of a pilot study in early breast cancer showing the analytical performance of the novel SBS® ...
By Tethis S.p.A
-
BioMark Receives Funding, Support, Research and Development Project for Cancer Treatment Monitoring
BIOMARK RECEIVES FUNDING SUPPORTING RESEARCH AND DEVELOPMENT PROJECT FOR CANCER TREATMENT MONITORING Vancouver, British Columbia – (February 7th, 2023) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF), an advanced stage liquid biopsy company with a focus on hard to detect and treat ...
-
SAGA Diagnostics raises SEK 106 million (€10.5 million) to accelerate commercialization of ultrasensitive cancer liquid biopsies
SAGA Diagnostics AB (“SAGA”), a cancer liquid biopsy and genomic testing company, today announced that it has raised SEK 106 million (€10.5 million) in a Series A2 financing from both existing and new investors. The Series A2 round was led by Segulah Medical Acceleration and the Sciety investment syndicate with strong support from existing shareholders such as Hadean Ventures. ...
-
miR Scientific to Present the Award-Winning Prostate Cancer Application of its Liquid Biopsy Disease Management Platform at the Jefferies Virtual Healthcare Conference
NEW YORK, June 3, 2021 /PRNewswire/ -- miR Scientific, LLC, a healthcare company dedicated to transforming global cancer management by providing early and highly accurate detection, characterization and monitoring of disease, announced today that its Chairman & CEO, Sam Salman, will be presenting at the Jefferies Virtual Healthcare Conference. Mr. Salman will discuss the planned commercial ...
-
miR Scientific to Present the Prostate Cancer Application of its Liquid Biopsy Disease Management Platform at the 39th Annual J.P. Morgan Healthcare Conference
NEW YORK, Jan. 11, 2021 /PRNewswire/ -- miR Scientific, LLC, a healthcare company whose purpose is to transform global cancer management by providing early and highly accurate detection, characterization and monitoring of disease, announced today that its Chairman & CEO, Sam Salman, will be virtually presenting at the 39th Annual J.P. Morgan Healthcare Conference. Mr. Salman will introduce ...
-
OncoDNA and Bergonié Institute to test the clinical utility of blood-and tissue-based biomarker tests in oncology
OncoDNA, a genomic and theranostic company specializing in precision medicine, and Bergonié Institute, a non-profit private hospital entirely devoted to fighting cancer, today announced a new clinical trial to evaluate the use of comprehensive biomarker testing and liquid biopsy in 700 patients diagnosed with an advanced metastatic cancer. The Appolo study will recruit patients from 6 ...
By OncoDNA S.A.
-
Biomark Announces Closing of $1,5 Million Financing Round to Accelerate Commercialization of Its Liquid Biopsy Technology
BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today that it has closed a financing round to accelerate the commercialization of its liquid biopsy technology. The financing round included a non-brokered private ...
-
Thermo Fisher Scientific Announces Oncomine Clinical Research Grant 2021 Call for Submissions
Thermo Fisher Scientific has opened a call for submissions for its Oncomine Clinical Research Grant program to support clinical research. The program aims to assist educational and independent research projects that exhibit excellence in molecular profiling to advance clinical outcomes and support health care providers serving cancer patients. After initially launching the grant program in 2020, ...
-
Winner announcement of EACR & Novosanis Research Grant: Cancer Biomarker Detection in Urine
We are pleased to announce that Dr Barbara Guinn from University of Hull UK is the winner of the EACR & Novosanis Grant for Cancer Biomarker Detection in Urine. The grant awards the most impactful proposal in cancer related research using urine as a sample type, which has shown to be an emerging non-invasive liquid biopsy. For urine sample collection, the Colli-Pee device will be provided by ...
By Novosanis NV
-
miR Scientific to Present the Prostate Cancer Application of its Liquid Biopsy miR Disease Management Platform® at the 12th Annual Prostate Cancer Awareness Day (PCAD) at the Massachusetts State House
NEW YORK, Feb. 25, 2021 /PRNewswire/ -- miR Scientific, LLC, a healthcare company whose purpose is to transform global cancer management by providing early and highly accurate detection, characterization and monitoring of disease, announced today that its Chairman & CEO, Sam Salman, will be virtually presenting at the 12th Annual Prostate Cancer Awareness Day at the Massachusetts State House ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you